BioAscent’s medicinal chemistry services are provided by our highly talented team of chemists, who have extensive experience of prosecuting successful drug discovery programmes gained within leading pharmaceutical and biotechnology companies. We understand the importance of making the right compound, not any compound, and that delivering a successful molecule with the appropriate biological, ADME and safety profile is set at the design stage.
Working in close partnership with you to understand your approach and project needs we can design and synthesise the optimal ligands for your project at all phases of the discovery process (Hit generation, Hit to Lead, Lead Optimisation). We assess and interpret the information from testing and rapidly incorporate it into the next design cycle thereby ensuring rapid progress. With our wealth of knowledge as drug hunters we can quickly and efficiently take your programme to success.
Our synthetic chemistry capabilities include multi-step synthesis of complex molecules, asymmetric synthesis, route design, building block synthesis, parallel synthesis of ligand arrays and reference molecules.
The synthetic chemistry team is supported by a range of in-house analytical techniques to ensure the quality of the output both for bespoke synthetic chemistry and for the compound library. These include: 400MHz NMR with multi-nuclei probe and variable temperature capability, LCMS analysis including UPLC, supercritical fluid chromatography to provide access to chiral analysis and preparative enantiomer separations.
Working in collaboration with partners at the German Cancer Research Center within the European Lead Factory project (ELF), BioAscent scientists helped discover potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases. This work has been published in ChemMedChem.
“More importantly, the scientists who were involved in the hit development stage, were fully committed to the success of the project, bringing their own ideas and solutions, which made my role as project owner very comfortable. I would be very happy to work with them again.”
Dr Aubry Miller, Cancer Drug Discovery/Wirkstoffforschung Group Leader, German Cancer Research Center (DKFZ)
Our chemistry team have worked on a broad range of target and ligand classes including:
Hydrolases, proteases (including serine, cysteine proteases), kinases (including protein, sugar kinases), phosphodiesterases, ligases, polymerases, nucleases, demethylases, deacetylases, methyltransferase, decarboxylases, dehydrogenases, oxygenases, reductases
Voltage and ligand-gated
Including splicing factors, chaperones, transporters
To support our talented team we have a comprehensive range of equipment, including:
Bruker Avance III 400 MHz NMR with multinuclear probe and 120-position carousel sample changer
Agilent 1200 and 1290 analytical LCMS systems with CTC autosamplers capable of both plate and vial-based sampling
Waters and Berger analytical/semi-prep SFC systems capable of achiral/chiral method development and separation with automated sample management
Waters fully automated semi-prep HPLC systems with diode array detection
Biotage Isolera automated purification systems with either dual wavelength or diode array detection
Genevac centrifuges with plate, vial and tube capability
Biotage Initiators with up to 60-sample capacity
Thales Nano H-Cube
Uniqsis Flowsyn Multi-X with high and low temperature capability
Extensive array of parallel synthesis equipment
ElectraSyn 2.0, Merck Photoreactor M1
In an industry standard, secure Dotmatics database
Posters & case studies